A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter Langmuir
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ordensklinikum Linz Gmbh, Servicestelle Für Studien
Linz, Austria
- Paracelsus Medical University Salzburg
Salzburg, Austria
- Hanusch Hospital
Vienna, Austria
- Vu Medical Center
Amsterdam, Netherlands
- Maastricht University Medical Center
Maastricht, Netherlands
- Erasmus Medical Center
Rotterdam, Netherlands
- Umc Utrecht Department of Hematology
Utrecht, Netherlands
- Arizona Oncology Associates
Tempe, Arizona, United States
- Uc Irvine Medical Center
Orange, California, United States
- Anschutz Cancer Pavilion - University of Colorado
Aurora, Colorado, United States
- Rocky Mountain Cancer Center
Colorado Springs, Colorado, United States
- Rocky Mountain Cancer Center
Denver, Colorado, United States
- Norwalk Hospital
Norwalk, Connecticut, United States
- Parkview Research Center
Fort Wayne, Indiana, United States
- University of Michigan Cancer Center
Ann Arbor, Michigan, United States
- Providence Cancer Center
Southfield, Michigan, United States
- Nebraska Cancer Specialist
Omaha, Nebraska, United States
- University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Willamette Valley Cancer Institute
Eugene, Oregon, United States
- Consultants in Medical Oncology and Hematology, Pc
Broomall, Pennsylvania, United States
- Texas Oncology - Round Rock Cancer Center
Round Rock, Texas, United States
- Texas Oncology San Antonio
San Antonio, Texas, United States
- Texas Oncology - Tyler
Tyler, Texas, United States
- University of Virginia
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Jan 2018
- Primary completion
- 14 Mar 2020
- Completion
- 1 Jun 2021
- Last update posted
- 16 Jun 2022
- Registered enrollment
- 23
- Registry id
- NCT03144687
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.